{"ok":true,"entity":{"id":"jazz-pharmaceuticals","name":"Jazz Pharmaceuticals plc","entityType":"company","officialName":"Jazz Pharmaceuticals plc","canonicalName":"Jazz Pharmaceuticals plc","displayName":"Jazz Pharmaceuticals plc","category":"睡眠・てんかん・がん領域のバイオ医薬品企業","shortDescription":"Jazz Pharmaceuticals plcはアイルランドで設立されダブリンに主たる事務所を置く、希少疾患を中心に睡眠障害、てんかん、がんの治療薬を手がけるグローバルなバイオ医薬品企業で、Nasdaq（JAZZ）に上場しています。2026年第2四半期の総収益は12億830万米ドルで、2026年9月15日にActio Biosciencesの買収を完了しました（2026年10月時点）。なお、ジャズ音楽や半導体企業のJazz Semiconductorとは無関係です。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.jazzpharma.com","updatedAt":"2026-10-22T11:50:32.298Z","secondaryClusters":[],"alias":["Jazz Pharmaceuticals","Jazz Pharma"],"searchKeywords":["Jazz Pharmaceuticals plc","ジャズ・ファーマシューティカルズ","JAZZ","Xywav","Epidiolex","Zepzelca","Ziihera","睡眠障害治療薬","希少疾患","アイルランド バイオ医薬品"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}